Literature DB >> 31669417

Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas.

Kirk E Evoy, Lindsey Groff, Lucas G Hill, William Godinez, Ravi Gandhi, Kelly R Reveles.   

Abstract

OBJECTIVE: Each U.S. state and the District of Columbia has passed legislation expanding access to naloxone, the opioid overdose antidote. Most naloxone access laws allow for standing orders, whereby prescribers may authorize pharmacists to dispense naloxone without an outside prescription. A recent study from our group assessing naloxone accessibility via standing order identified continued access barriers. The present study assessed whether brief, in-person, student-led academic detailing of community pharmacists improved naloxone accessibility.
METHODS: A telephone audit of all 2317 CVS, Walgreens, H-E-B, and Walmart pharmacies in Texas was conducted to determine naloxone accessibility under standing orders. Within 2 months following the initial audit, student pharmacists visited the Austin and San Antonio, Texas area pharmacies that indicated they would not dispense naloxone without a prescription, to provide brief (< 5 minutes) academic detailing to the pharmacist on duty. Students followed a scripted outline designed to inform pharmacists about naloxone standing orders and naloxone use for opioid overdose response. Then they provided a flyer and requested that it be displayed in the pharmacy to inform patients about naloxone. An identical telephone audit was conducted 1-2 weeks following the education.
RESULTS: Of the 49 pharmacies receiving education, 37 (76%) responded that they would dispense naloxone without an outside prescription appropriately. When comparing each pharmacy before and after detailing, respectively, it was observed that 51% versus 71% (P = 0.008) stocked naloxone; 43% versus 71% (P = 0.002) would dispense naloxone to a third-party customer; and 12% versus 37% (P = 0.005) would submit a claim to the insurance of a third-party customer.
CONCLUSION: Student-led academic detailing was effective in improving pharmacists' willingness to dispense naloxone under standing orders and increasing naloxone accessibility from community pharmacies. Studies beyond Texas chain pharmacies are warranted to validate the effectiveness of this technique on a larger scale.
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31669417     DOI: 10.1016/j.japh.2019.09.007

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  6 in total

1.  Pharmacists' experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study.

Authors:  Robin A Pollini; Susannah Slocum; Jenny Ozga; Rebecca Joyce; Ziming Xuan; Traci C Green; Alexander Y Walley
Journal:  J Am Pharm Assoc (2003)       Date:  2021-08-23

2.  Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.

Authors:  Robin A Pollini; Jenny E Ozga; Rebecca Joyce; Ziming Xuan; Alexander Y Walley
Journal:  Drug Alcohol Depend       Date:  2021-12-31       Impact factor: 4.492

3.  Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018.

Authors:  Christopher Dunphy; Kun Zhang; Gery P Guy; Christopher M Jones
Journal:  Prev Med       Date:  2021-09-29       Impact factor: 4.637

Review 4.  Academic detailing interventions for opioid-related outcomes: a scoping review.

Authors:  Victoria Kulbokas; Kent A Hanson; Mary H Smart; Monika Rao Mandava; Todd A Lee; A Simon Pickard
Journal:  Drugs Context       Date:  2021-12-15

Review 5.  Primary care management of Long-Term opioid therapy.

Authors:  Phillip O Coffin; Rebecca S Martinez; Brian Wylie; Bunny Ryder
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

Review 6.  Considering the Potential Benefits of Over-the-Counter Naloxone.

Authors:  Kirk E Evoy; Lucas G Hill; Corey S Davis
Journal:  Integr Pharm Res Pract       Date:  2021-02-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.